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Introduction
Gene therapy promises considerable advances in the treatment of several important diseases, and a number of elegant molecular strategies have been designed. Putting the theory into practice is not straightforward, however, and therapeutic usefulness is continually frustrated by inadequate systems for gene delivery. Of particular concern is the absence of systems capable of systemic gene targeting following intravenous injection, 1, 2 and the great majority of therapeutic studies carried out to date have involved local protocols of gene administration. 3 There are several pre-requisites of a versatile vector for systemic gene delivery, including safety, full definition, good biocompatibility, flexible targeting tropisms and small size (to permit efficient extravasation into target tissues). Probably the single most important property required is the ability to undergo prolonged circulation in the plasma, increasing opportunities for interaction of targeting ligands with their receptors, and also, in the case of cancer, maximising passive targeting mechanisms. 4, 5 The pharmacokinetics of synthetic vectors based on cationic liposomes seem generally limited, with most forms being extracted from the bloodstream in the first capillary bed encountered, although recently, more sophisticated cationic lipid-based forms have shown improved distribution profiles. 6 Correspondence: LW Seymour Received 17 March 1998; accepted 16 October 1998 We are using synthetic polymers to develop selfassembling gene delivery vectors, intended for systemic targeting and designed for efficient transfection of target cells remote from the site of intravenous injection. [7] [8] [9] However, it is well known, although not widely published, that simple polycation/DNA complexes undergo rapid clearance from the plasma following intravenous administration. This constitutes a significant obstacle to development of such polycation/DNA complexes in vivo, and has restricted attempts to develop targeted polyelectrolyte vectors for systemic use.
In this study we report the plasma kinetics and body distribution of poly(l-lysine) (pLL)/DNA complexes and examine mechanisms possibly mediating their rapid blood clearance. No evidence was found for rapid nucleolytic degradation in vivo, and complement activation could not be detected using appropriate in vitro model systems. However, there were indications of significant binding of complexes to serum proteins, including albumin. This could lead to opsonisation and scavenging of the complexes by phagocytes, or could loosen and enlarge the complexes resulting in physical trapping in microcapillaries. Possible means to stabilise complexes against protein binding and consequent rapid clearance are discussed.
Results
Distribution kinetics of pLL/DNA complexes The blood clearance rate and body distribution of pLL/DNA complexes (N:P ratio 2.0) containing 32 P-radi-olabelled DNA was determined following intravenous injection into BALB/c mice. No mice showed any signs of toxicity or anaphylactic responses during the study. Complexes were cleared rapidly from the bloodstream with at least bi-exponential clearance kinetics, with an ␣ half-life of less than 5 min (Figure 1 ). The profile of blood clearance was indistinguishable from that of free 32 P-DNA. After 30 min the body distribution of pLL/DNA complexes formed at N:P 1.0 and 2.0 were similar, and also similar to free 32 P-DNA (Figure 2 ). In all cases there was some deposition in muscle, skin and intestines, but the majority of radioactivity (over 50% of the dose administered) was recovered in the liver. The pLL/DNA complexes showed slight, but reproducible, elevation in levels determined in the blood after 30 min compared with 32 P-DNA.
Determination of complement activation
The possibility of activation of the complement system by pLL/DNA complexes was investigated using standard radial immunodiffusion protocols to measure activation of the classical and alternative pathways, and also to determine levels of C3d. Behring nephelometry was used to measure C3 and C4 levels directly (Table 1) . No significant activation of complement cascades was observed by pLL/DNA complexes formed at N:P ratios 0.8 and 2.0, compared with untreated serum as control. Furthermore, there were no significant changes in the levels of the complement components C3, C4 and levels of the C3 degradation product C3d were normal, indicating that there was no significant opsonisation of the pLL/DNA complexes by the complement system.
Agarose electrophoresis of pLL/DNA complexes exposed to human serum Agarose gel electrophoresis was used to analyse the interaction of fresh human serum with DNA and with 21 (n = 3). pLL/DNA complexes ( Figure 3 ). Free DNA ran into the gel (lane 1), and showed a slightly decreased motility in the presence of albumin (lane 2), whereas serum caused a significant retardation of movement (lane 3). Conversely, pLL/DNA complexes remained in the wells during electrophoresis (lane 4) and could not be visualised by UV as the ethidium bromide in the gel is not able to bind to the condensed DNA. The complexes could be visualised by post-electrophoretic incubation of the gel in heparin (data not shown). Incubating complexes in 50% serum before electrophoresis caused an increase in the fluorescence in the wells (lane 6), suggesting that some serum components are able to interact with pLL/DNA complexes and either dissociate the complexes completely or disrupt them enough to allow ethidium bromide into the DNA structure. Similar results were obtained using complexes preincubated in albumin only (lane 5), suggesting that free DNA was probably not released from the complexes, since it is known to migrate effectively in the presence of albumin alone (lane 2). This indicates the formation of a slightly fluorescent ternary pLL/DNA/albumin complex that remains in the well. Albumin and other serum proteins produced a faint and relatively mobile signal with ethidium bromide that could be distinguished at the right hand side of the gel (lanes 2, 3, 5-8).
Figure 2
Isolation of pLL/DNA complexes from serum and identification of bound proteins pLL/DNA complexes containing 32 P-labelled DNA were formed at N:P ratios of 1.0 and 2.0 and then incubated in whole serum, re-isolated by centrifugation and analysed by SDS-PAGE with silver staining to determine the with polycations. 7, 10 The ability of polyanions to strip off the polycations, reflected in restoration of ethidium bromide/DNA fluorescence, has been used previously as a measure of complex stability. 7 The effects of albumin on restoration of ethidium bromide/DNA fluorescence was therefore examined, using pLL/DNA complexes prepared at N:P ratios of 1.0 and 2.0.
The addition of albumin to pLL/DNA complexes in water results in significant turbidity that may interfere with the determination of ethidium bromide/DNA fluorescence. 11 The spectral effects of turbidity, and its possible interference with ethidium bromide/DNA fluorescence, were examined using a fixed 590 nm emission and scanning the excitation wavelength. Figure 5 shows that there is a significant signal from pLL/DNA complexes (without ethidium bromide), probably resulting from light scattering, at all excitation wavelengths rang- ing from 350 nm up to 480 nm. At higher excitation wavelengths (480-560 nm) the signal resulting from light scattering is relatively low. Fluorescence of ethidium bromide/DNA shows a significant maximum at excitation 510 approximately, in addition to the signal generated at excitation 366 nm and lower. Hence the excitation wavelength 510 nm seems likely to combine good resolution of fluorescence, with relatively little input from light scattering. A 515 nm cut-off filter was included in the detection system to improve resolution further. Figure 6a shows that pLL/DNA complexes display a gradual increase in relative fluorescence as albumin is sequentially added to the mixture. The level of fluorescence reached is greater for complexes formed at N:P 1.0 than it is for N:P 2.0. Control studies (Figure 6b ), performed in the absence of ethidium bromide, showed no significant signal produced by adding albumin to complexes formed at N:P 1.0. However, complexes formed at N:P 2.0 showed a sudden increase in signal after the addition of approximately 0.5 mg/ml albumin, which then diminished slightly with further albumin addition. This effect is thought to reflect turbidity resulting from binding of albumin to free pLL. Albumin alone, with ethidium bromide, gave no significant fluorescence or turbidity signal.
Effect of albumin binding on the surface charge of pLL/DNA complexes Zeta potential analysis was used to investigate the effect of albumin binding on the surface charge of pLL/DNA complexes (N:P ratio 2.0). The surface charge of untreated complexes (48 ± 0.5 mV) was decreased to 37 ± 3.8 mV following the addition of 20 g/ml albumin (Figure 7) , and 200 g/ml albumin decreased the zeta potential further to 4 ± 0.8 mV. Albumin concentrations of 400 g/ml and above produced negative zeta potentials, reaching a minimum at about 1 mg/ml. Incubating pLL/DNA complexes in serum (2.5%) was found to decrease the surface charge to −16 ± 2.5 mV, while incu- bation in the corresponding concentration of albumin (1 mg/ml) also resulted in a measured zeta potential of −16 ± 0.5 mV (Figure 7 , inset).
Effect of albumin and serum interactions on the transfection efficiency of pLL/DNA complexes The influence of serum and commercial serum albumin on transfection efficiency of pLL/DNA complexes was compared against 293 cells. The presence of 10% serum reduced transfection efficiency approximately 97%, while the corresponding concentration of albumin (3.5 mg/ml) had a virtually identical effect (Figure 8 ). This suggests that albumin binding to pLL/DNA complexes exerts a significant inhibition of transfectional activity, probably either interfering with electrostatic or hydrophobic binding to the plasma membrane, or inhibiting cellular internalisation.
Discussion
Safe and efficient targeted vectors for systemic delivery of genes would have several useful applications in various branches of medicine. For reasons of safety and economy it is desirable that such vectors should be completely synthetic, however vectors based on cationic liposomes are usually cleared from the bloodstream quickly, often becoming deposited in the pulmonary microvasculature. 12, 13 In attempting to design systems capable of better pharmacokinetics we have examined the biodistribution and blood clearance of self-assembling vectors based on DNA condensed with cationic polymers to give polyelec- trolyte complexes. Complexes formed between pLL and 32 P-labelled DNA were cleared rapidly from the bloodstream, showing deposition after 30 min mainly in the liver but also in association with organs with fine capillary beds such as the skin, muscle and intestine. There was very little urinary excretion, and no significant accumulation in the heart or lungs.
There are several possible mechanisms that might contribute to the rapid blood clearance of pLL/DNA complexes, including rapid degradation by nucleases, activation of complement, opsonisation and phagocytosis or filtering by capillary beds. [13] [14] [15] In this study, we have examined several possible factors to determine whether they appear to contribute to the distribution kinetics observed here.
Results suggested no significant involvement of complement in mediating rapid blood clearance of complexes, using established assay procedures and pLL/DNA concentrations and durations of exposure chosen to mimic the conditions in vivo. There was no activation of either the classical or alternative pathways, and C3d levels were found to be normal. In addition, the extremely fast rate of blood clearance observed here, if mediated by complement, would normally be accompanied by symptoms of anaphylaxis. None were observed, and it therefore seems unlikely that complement fixation is playing a significant role in the rapid blood clearance observed. The results of Plank et al 14 were obtained using relatively high concentrations of high molecular weight cationic polymers to achieve measurable complement-mediated haemolysis in vitro. It is feasible that the complexes employed here might activate complement over a longer time scale if they were maintained in the circulation for a longer period.
An alternative explanation proposed for rapid clearance of free DNA concerns rapid degradation by circulating nucleases. 13 However, there is a significant body of literature showing that polycation/DNA complexes are relatively resistant to degradation by serum nucleases. 15 Indeed, we have previously demonstrated, 7 that pLL/DNA complexes are resistant to degradation by 90% serum, requiring the action of purified nuclease preparations to achieve significant degradation over relatively short time scales. It therefore seems unlikely that nuclease degradation accounts for the rapid blood clearance observed. This is supported by the slow rate of renal excretion, with less than 7% of the radioactivity measured in the urine after 30 min.
pLL/DNA complexes undergo noticeable physicochemical changes following the addition of small amounts of serum. When analysed by agarose gel electrophoresis in the presence of ethidium bromide, pLL/DNA complexes regain a level of fluorescence although the signal fails to migrate, even though the complex is known to bear a significant negative zeta potential. This suggests the DNA is forming part of a supramolecular complex which is physically incapable of penetrating the agarose gel.
To identify the serum factor or factors that interact with pLL/DNA complexes, complexes preformed at N:P ratios of 1.0 and 2.0 were incubated in serum, re-isolated by centrifugation and analysed by SDS-PAGE. Albumin appeared to be the major protein bound in each case, and more was bound at N:P ratio 1.0 than 2.0. This suggests that albumin may be binding at least partially through hydrophobic interactions rather than simply electrostatic ones. Other proteins were also detected, particularly in association with the N:P 1.0 complexes. These included several low molecular weight bands, but one large and distinct band at about 200 kDa that could represent complement C3. Any or all of the proteins could be serving as opsonins, increasing cellular interactions of the complexes, accelerating blood clearance and perhaps promoting phagocytosis.
Albumin was shown to bind effectively to pLL/DNA complexes in vitro, restoring some fluorescence of ethidium bromide/DNA and also inducing significant turbidity. To permit discrimination of ethidium bromide/DNA fluorescence from turbidity-related light scattering, wavelengths of 510 ex and 590 em were used, with a cut-off filter at 515 nm. Restoration of ethidium bromide/DNA fluorescence by albumin was greater at N:P 1.0 than 2.0, compatible with the observation that more albumin bound to the complexes at this charge ratio. In addition, agarose gel electrophoresis showed that albumin was able to form a ternary complex with pLL and DNA, the resulting complex remaining at the origin and fluorescing in the presence of ethidium bromide. Other serum proteins, notably immunoglobulin G and fibronectin, were unable to mediate any noticeable effects on the complexes. It would be interesting to examine any interaction of C3 with complexes. Interestingly, simple DNA failed to migrate on an agarose gel in the presence of serum (but not in the presence of albumin alone), suggesting its binding to serum factors other than albumin. It is possible that these proteins, so far not identified, could contribute to the rapid plasma clearance of DNA and even of pLL/DNA complexes.
The positive surface charge (zeta potential) of pLL/DNA complexes prepared at a 2:1 N:P ratio was decreased in the presence of serum (2.5%) to −16 mV. The addition of the equivalent concentration of serum albumin also decreased the zeta potential to −16 mV, adding further circumstantial evidence that albumin may be the dominant factor in serum which modifies the surface of these complexes.
Binding of serum albumin to pLL/DNA complexes was also shown to decrease significantly the transfection activity of the complexes in 293 cells. This could result from less binding to the negatively charged cell surface following the change in the surface charge of complexes from positive to negative mediated by binding of albumin. Alternatively, binding of albumin may increase the size of the complexes, perhaps preventing entry into cellular endocytic pathways.
Studies with liposomes have shown that the association of plasma proteins with the liposome has a major role in clearance from the bloodstream. 16, 17 Liposomes have been isolated from the bloodstream and bound proteins analysed by SDS-PAGE, using technology analogous to that described here. Several proteins have been found to bind, including many opsonins such as IgG, complement C3 and fibronectin, sometimes nearly 50 g of protein per mole of total lipid. Incorporating cholesterol (50 mol %) into the liposome preparation results in a four-fold reduction in the amount of bound protein and a corresponding increase in the half-life in the liposomes in the bloodstream (from a few seconds to over 5 h). This suggests that liposomes with a larger amount of plasma proteins associated with them are more likely to be recognised by the reticuloendothelial system (RES) and cleared from the bloodstream. 16 We propose that when pLL/DNA complexes, bearing a neutral or net positive charge, are injected intravenously, they quickly bind albumin and other plasma proteins, forming an extended ternary complex with a net negative surface charge. This ternary complex still resists immediate degradation by serum nucleases (data not shown), but may promote phagocytic capture, particularly by Kupffer cells, and small levels of material may also become entrapped in the fine capillary networks of several organs, notably the muscle, skin and intestines. The kinetics of distribution for pLL/DNA complexes are largely independent of N:P ratio and similar to the kinetics of free DNA. Hence, an alternative explanation is conceivable, namely that the pLL is removed from the complex quickly following entry into serum, releasing free DNA. This is thought not to be the case, however, since DNA pre-complexed to pLL can be reisolated from serum efficiently by centrifugation, while simple DNA cannot be reclaimed in this way.
Throughout these studies, the interaction of pLL/DNA complexes with serum proteins has been examined with pLL/DNA complexes bearing neutral or slight positive charges. Although it is an attractive possibility to use polyelectrolyte complexes with a less positive surface charge, pLL/DNA complexes usually exert their optimal transfection activity in vitro at positive N:P ratios. Hence, it seems likely that optimal strategies for targeted transfection in vivo will employ complexes with an excess positive charge, with the inherent problems of albumin binding. It may be feasible to bypass this problem by making use of polyelectrolytes based on cationic polymers with pKa values in the endosomal range, such as polyethyleneimine. 18, 19 Such complexes could in principle display a net negative charge while in the circulation, taking on a more membrane active structure following protonation during endosomal acidification.
It seems likely, however, that negatively charged polycation/DNA complexes may be subject to similar disruption by positively charged serum proteins, including opsonins such as IgG which are known to contribute to rapid clearance of simple liposomes, 20, 21 and they may also be scavenged by the macrophage polyanion receptor. 22 Negatively charged polycation/DNA complexes are also less fully condensed, forming larger particles, and are expected to be more susceptible to degradation by serum nucleases. 13 It seems likely that all forms of polyelectrolyte DNA complexes may require stabilisation to improve their circulation times in vivo.
There are several possible approaches to stabilising polycation/DNA complexes against protein binding. One strategy could be to enshroud the polyelectrolyte complex within a protective layer of hydrophilic polymers, analogous to STEALTH liposome technology. This could be introduced by oriented self-assembly of DNA with cationic-hydrophilic block co-polymers 8 or by surface modification of pre-formed polyelectrolyte complexes. These approaches, and others, are currently being developed in our laboratories.
Materials and methods
DNA purchase and preparation A circular 6.4 kb expression vector containing a CMV promoter-driven ␤-galactosidase reporter gene and ampicillin resistance was used for all examinations of biological properties. This was prepared by growth in E. coli DH5␣ and purified using Qiagen columns (Dorking, UK). Following the final ethanol precipitation the purity of the DNA was checked by agarose gel electrophoresis. Fluorimeter-based assays measuring ethidium bromide fluorescence were performed using calf thymus DNA, average molecular size 8 kb (Sigma Chemical, Poole, UK), due to the relatively large size of samples required.
Formation of polyelectrolyte pLL/DNA complexes pLL (hydrobromide salt) was purchased from Sigma Chemical, and a molecular mass per amino group of 209 Da was used for calculation of N:P ratios. For DNA a mass per phosphate of 325 Da was used. Complexes were formed in water by adding pLL solution (5 mg/ml, volume dependent on desired N:P ratio) with gentle mixing to a solution of DNA, reaching a final DNA concentration of 20 g/ml.
Radiolabelling of DNA expression vectors Plasmid DNA was linearised with HindIII and then radiolabelled with 32 P-dCTP using the Ready-to-Go Oligolabelling kit (Pharmacia Biotech, St Albans, UK). Unincorporated nucleotides were removed using MicroSpin columns (Pharmacia Biotech) and the purity of the labelled DNA checked following agarose gel electrophoresis and quantitative analysis with a PhosphoImager (Molecular Dynamics, Chesham, UK).
Determination of plasma clearance and body distribution
Complexes were formed between pLL and expression vector DNA, containing a spike of 32 P-labelled DNA, at cation:anion N:P ratios of 1.0 and 2.0. Complexes were diluted with an equal volume of 10% glucose solution and immediately administered via the tail vein to briefly anaesthetised 6-week-old female BALB/c mice. Free 32 P-DNA was administered in control experiments. Serial blood samples were isolated every 5 min and accurately weighed before measurement of their contained radioactivity. After 30 min the animals were killed and dissected to permit determination of radioactivity distribution. Organs were either homogenised or dissolved in sodium hydroxide (10 N), before geometry-corrected analysis of their contained radioactivity in a Packard scintillation counter. A bloodstream volume of 8.64 ml/100 g body weight was assumed, 23 and the component of muscle and skin was assumed to be 45% and 16% of the total body weight, respectively. 24 Determination of complement activation in vitro pLL/DNA complexes were formed at N:P ratios of 2.0 and 0.8 and were incubated in full human serum for either 20 or 60 min at 37°C. Radial immunodiffusion (RID) assays were performed on the samples to determine the levels of alternative and classical pathway activation, as well as the level of C3d production. RID plates were obtained from The Binding Site, Birmingham, UK. Levels of C3 and C4 were measured directly by standard procedures using the Behring nephelometry assay. 25 Agarose gel electrophoresis pLL/DNA complexes prepared at cation:anion N:P ratio of 2 in water were electrophoresed on agarose gel (0.8 % w/v) for 45 min at 90 V. Ethidium bromide was included in the gel to show the location of DNA using a UV transilluminator. In certain experiments, foetal calf serum (FCS) or bovine albumin was mixed with the complexes before electrophoresis.
Isolation of complexes from serum and analysis of protein binding pLL/DNA complexes containing 32 P-labelled DNA were allowed to assemble for 30 min in water, N:P ratio 1.0 and 2.0, and then incubated in non-heat-treated foetal calf serum (50% solution, 1 h, 37°C). Samples (2 ml) were loaded carefully on to a water layer (3 ml) above a simple sucrose cushion (45% w/v, 2 ml). Samples were then centrifuged in a Beckman (High Wycombe, UK) Ultracentrifuge L 2 65B (120 000 g, 12 h) to pellet the complexes. Tubes were then frozen in liquid nitrogen, and the bottom 1.0 ml (approximately) removed with a razor blade. The sample was allowed to thaw, supernatant sucrose removed and the 32 P-labelled pellet was resuspended in water. Recovery of DNA was checked by measuring the radioactivity sedimented. Complexes were dissociated and denatured by boiling in mercaptoethanol/SDS, and proteins were visualised on a 12.5% acrylamide gel (Hoeffer (San Francisco, CA, USA) Minigel, 25 mA, 80 min) with detection using diamine silver. 26 To permit standardisation complexes were applied at a level of 1.2 g DNA per lane.
Ethidium bromide/DNA fluorescence restoration assay
The ability of albumin to restore fluorescence to pLL/DNA complexes was examined using a Perkin Elmer (Buckinghamshire, UK) LS50B fluorimeter. DNA (20 g/ml) was incubated in water with ethidium bromide (400 ng/ml), and polyelectrolyte complexes were formed at a cationic N:P ratio of 2.0 by adding pLL solution (5 mg/ml, 5.1 l). Complexes were then incubated for 30 min at room temperature in order to ensure stabil-isation. BSA solution (10 mg/ml) was added stepwise (2 l steps) to the complexes and changes in fluorescence were monitored. Studies were performed at an emission wavelength of 590 nm, with excitation wavelength varied as described in the text. Optimal methodology involved excitation at 510 nm, with a 515 nm cut-off filter used to improve signal to noise ratio for fluorescence determination.
Measurement of zeta potential
Complexes were formed at a DNA concentration of 40 g/ml in water and subject to various additions or changes of buffer as described in the text. Surface charge was measured at a final DNA concentration of 20 g/ml using a Zetamaster (Malvern Instruments, Malvern, UK).
Transfection with pLL/DNA complexes in the presence or absence of serum Transfections were performed following established protocols. 8 Briefly, 293 cells were cultured at 37°C in 75 cm 2 flasks in Dulbecco's modified Eagle's medium containing 10% FCS. Before transfection the cells were plated into 96-well plates at a cell density of 8500 per well. After 24 h, the medium was removed and replaced with fresh, serum-free medium containing chloroquine (100 m) and pLL/DNA complexes (N:P ratio 4.0, containing pLL of molecular weight 54 K with a final DNA concentration of 2.5 g/ml). After 5 h the medium was removed, replaced with serum-containing medium and the cells left for 48 h. After this time the cells were lysed and the presence of ␤-galactosidase assayed using the Galactolight kit (Tropix, Cambridge, UK) and enzyme activity expressed as light units per g protein.
